The High Stakes Gamble of Biotech Investing: Where Hope Meets Uncertainty The biotech sector has been marked by extreme volatility, with stocks fluctuating wildly as companies pursue the next breakthrough.
Beneath this surface lies a complex web of risks and uncertainties that can make even seasoned investors nervous. One reason for this volatility is the nature of drug development itself.
According to a recent study by the Biotechnology Innovation Organization, only about 15% of treatments that reach phase 2 trials advance to phase 3 – a decade long journey requiring repeated proof of safety and efficacy.